



OBIL/BSE/25/2020-2021

Oceanaa Biotek Industries Limited

CIN : L15549TN2005PLC057919

GSTIN : 33AAACO8057E1ZM

E : obil@oceanaabiotek.com

www.oceanaabiotek.com **11th November, 2020**

To,
The Corporate Relations Department
The Bombay Stock Exchange Ltd,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

Sub: Submission of Standalone unaudited Financial Results for the quarter and half yearly ended 30 September, 2020.

This is to inform you that the meeting of the Board of Directors was held on 11th November, 2020 to consider and approve the following

- Standalone Unaudited Financial Results for the quarter and half yearly ended 30.09.2020.

The following documents are enclosed herewith:


- Standalone Audited Financial Results for the quarterly and year ended 30.09.2020.
- Limited Review Report signed by Statutory Auditor
- Certification by Managing Director as per Regulation 33(2)(a) of SEBI ((Listing Obligations and Disclosure requirements) Regulations, 2015.

The meeting commenced at 03.30 p.m. and concluded at 06:30 p.m.

Kindly update the above in your records.

For Oceanaa Biotek Industries Limited

T Xavier Jeyaraj
Managing Director
Encl: As above



M/S. OCEANAA BIOTEK INDUSTRIES LIMITED
CIN: L15549TN2005PLC057919

Flat No. C-4, Ceebros Apartments, No. 2, Saravana Street, T Nagar, Chennai - 600017

Unaudited Standalone Financial Results for the Quarter and Half Year Ended 30th Sep 2020

(Rs in Lakhs)

S.No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		9/30/2020 (Unaudited)	6/30/2020 (Unaudited)	9/30/2019 (Unaudited)	9/30/2020 (Unaudited)	9/30/2019 (Unaudited)	3/31/2020 (Audited)
1	Revenue from Operations						
	a) Sale of products	354.04	453.47	524.48	807.51	901.32	2,565.50
	b) Other Operating Revenues					-	
	Total Revenue from Operations	354.04	453.47	524.48	807.51	901.32	2,565.50
2	Other Income	-	-	-	-	156.00	2.62
3	Total Income (1+2)	354.04	453.47	524.48	807.51	1,057.32	2,568.12
4	Expenses						
	a) Cost of Materials Consumed	128.52	160.73	171.28	289.25	740.88	1,063.77
	b) Purchase of Stock-in-Trade		-		-	-	-
	c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-Trade"	44.25	(79.69)	6.69	(35.44)	-	(20.71)
	d) Employee Benefits Expense	33.38	22.94	28.97	56.33	37.09	130.84
	e) Depreciation and Amortisation Expense	46.18	45.59	54.45	91.77	51.95	216.60
	f) Finance Costs	1.49	1.67	2.08	3.16	22.84	7.57
	g) Other Expenses	77.08	159.08	123.80	236.16	114.39	920.84
	Total Expenses	330.90	310.32	387.27	641.22	967.15	2,318.91
5	Profit Before Exceptional Items and Tax (3 - 4)	23.14	143.15	137.22	166.29	90.17	249.21
6	Exceptional Items [Refer Note 4]	-	-	-	-	-	-
7	Profit Before Tax (5 + 6)	23.14	143.15	137.22	166.29	90.17	249.21
8	Tax Expense						
	i. Current Tax	3.62	22.50	9.09	26.12	24.42	-
	ii. Deferred Tax	0.41	0.24	2.08	0.65	(24.73)	(39.00)
	Total (i - ii)	3.21	22.26	7.01	25.47	(0.31)	39.00
9	Profit After Tax (7 - 8)	19.93	120.89	130.20	140.82	90.48	210.21
10	Other Comprehensive Income						
	"a) Items not to be reclassified to profit or loss in subsequent periods"	-	-	-	-	(13.00)	0.31
	"Re-measurement Gains and (Losses) on Defined Benefit Obligations (Net) and Net (Loss)/Gain on FVTOCI Equity Securities"	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	"b) Items to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	-
	Net movement on cash flow hedges	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	Other Comprehensive Income for the period	-	-	-	-	(13.00)	0.31
11	Total Comprehensive income (9 + 10)	19.93	120.89	130.20	140.82	77.48	210.52
12	Paid-up Equity Share Capital (Face Value of 10 Each)	135,652,750	135,652,750	135,652,750	135,652,750	102,632,000	135,652,750
13	Earnings Per Share (Face Value Rs. 10/- per Share) - Not Annualised						
	- Basic (in Rs.)	0.15	0.89	0.96	1.04	0.88	1.55
	- Diluted (in Rs.)	0.15	0.89	0.96	1.04	0.88	1.55

Notes:

- The Audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 11th Nov, 2020
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Sec 133 of the Companies Act'2013 and other recognised accounting practices and policies to the extent applicable.
- Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the Quarter ended September 2020 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were no Investors' Complaints received during the period.
- All the financial numbers presented above are prepared as per the IND AS.
- The Company has considered the possible effects that may result from COVID-19 in the preparation of these standalone financial results including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of COVID-19, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information which are relevant and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial results may differ from that estimated as at the date of approval of these standalone financial results. However, the impact assessment of COVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any and make any necessary adjustments in the relevant financial period.

For and on Behalf of Board of Directors



Thomas Xavier Jeyaraj
Managing Director
DIN: 06896574

Place: Chennai
Date: 11-Nov-2020

M/S. OCEANAA BIOTEK INDUSTRIES LIMITED

CIN: L15549TN2005PLC057919

Flat No. C-4, Ceebros Apartments, No. 2, Saravana Street, T Nagar, Chennai - 600017

Unaudited Standalone Statement of Assets & Liabilities

(Rs in Lakhs)

PARTICULARS		As at 30th Sep 2020 Unaudited	As at 31 st March 2020 Audited
A	ASSETS		
1	Non-current assets		
	Property, Plant and Equipment	1,359.67	1,449.76
	Capital Work-in-progress	650.00	650.00
	Total Non-Current Assets	2,009.67	2,099.76
2	Current assets		
	(a) Inventories	110.44	74.99
	(b) Financial Assets		-
	(i) Trade Receivables	801.04	527.08
	(ii) Cash and cash equivalents	15.31	13.64
	(iii) Other financial assets	51.82	53.40
	(c) Current Tax Assets (net)	0.15	0.15
	(d) Other current assets	1,325.96	1,333.49
	Total Current Assets	2,304.73	2,002.76
	TOTAL ASSETS	4,314.40	4,102.52
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	1,356.53	1,356.53
	(b) Other Equity	1,521.13	1,380.32
	Total Equity	2,877.66	2,736.84
2	LIABILITIES		
	Non-current liabilities		
	(a) Borrowings	61.03	75.47
	(b) Provisions	1.81	1.81
	(c) Deferred tax Liabilities (Net)	39.58	40.23
	Total Non-Current Liabilities	102.42	117.52
	Current Liabilities		
	(a) Financial Liabilities		
	(i) Trade Payables	421.54	355.18
	(iii) Other Financial liabilities	42.77	50.07
	(b) Other current liabilities	15.74	14.77
	(c) Provisions	854.27	828.15
	Total Current Liabilities	1,334.31	1,248.16
	Total Liabilities	1,436.74	1,365.68
	TOTAL EQUITY AND LIABILITIES	4,314.40	4,102.52
	Summary of significant accounting policies		
	Notes on Accounts		

For and on Behalf of Board of Directors



Thomas Xavier Jeyaraj
Managing Director
DIN: 06896574

Place: Chennai
Date : 11-Nov-2020

M/s.Oceanaa Biotek Industries Limited

CIN:L15549TN2005PLC057919

Flat No.C-4, Ceebros Apartments, No.2, Saravana Street, T Nagar, Chennai, Tamil Nadu - 600017

UNAUDITED STANDALONE CASH FLOW STATEMENT

(Rs in Lakhs)

Particulars	Half-Year Ended 30-Sep-20 Unaudited	Half-Year Ended 30-Sep-19 Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before taxes	23.14	137.22
Adjustment for:		
Depreciation	46.18	54.45
Interest Income	-	-
Operating profit before working capital changes	69.32	191.66
Adjustment for increase/ (-) decrease in		
Inventory	44.25	6.69
Trade receivables	(122.12)	(139.96)
Loans, advances and other current assets	7.23	(15.71)
Trade payables	6.31	(15.77)
Other current liabilities	3.71	(14.43)
Short term provisions	3.62	5.74
Long term provisions	-	(3.46)
Cash generated from / (used in) operations	12.32	14.76
Exceptional Item	-	-
Less: Current year provision / Taxes paid	3.62	9.09
Net cash flow from operating activities (A)	8.70	5.67
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase for fixed assets	-	-
Expenditure on property, plant and equipment	-	-
Loss of Fixed Assets	-	-
Interest income	-	-
Net cash flow/used in from investing activities (B)	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from long term borrowings (Net)	(7.29)	(6.73)
Repayment of short term borrowings	-	0.93
Premium on equity shares	-	-
Issue of equity shares	-	-
Dividend paid	-	-
Net cash flow from financing activities (C)	(7.29)	(5.81)
Net increase/decrease in cash and cash equivalents (A+B+C)	1.41	(0.14)
Cash and cash equivalents (Opening balance)	13.91	10.82
Cash and cash equivalents (Closing balance)	15.31	10.68
Components of cash and cash equivalents:		
Cash on hand	0.28	5.04
Balance with Banks	3.53	5.64
Term deposits with bank	11.50	-

For and on Behalf of Board of Directors



Thomas Xavier Jeyaraj
Managing Director
DIN: 06896574

Place: Chennai
Date : 11-Nov-2020

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
M/s OCEANAA BIOTEK INDUSTRIES LTD

Limited Review Report of the Unaudited Financial Results for the quarter ended 30th September, 2020

We have reviewed the accompanying Statement of Unaudited Financial Results of M/s. OCEANAA BIOTEK INDUSTRIES LIMITED ("the Company") for the quarter ended 30th September, 2020 and year to date from 1st April, 2020 to 30th September, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Regulation") as amended (the "Listing Regulations"), read with SEBI Circular No. CIR/CFD/CM1/80/2019 dated 19th July, 2019 ("the Circular").


This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chennai
Date: 11/11/2020

For ABHAY JAIN & CO.
Chartered Accountants
FRN: 000008S



(A.K. Jain)
MNO. 070224

UDIN: 20070224AAAACU3688



Date: 11th November, 2020

DECLARATION


M/s Abhay Jain & Co., Chartered Accountants, Statutory Auditor of the Company has given an unmodified opinion with respect to the Standalone unaudited Financial Results for the quarter ended 30th September, 2020.

This declaration is submitted in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2016, as issued by SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May, 25, 2016.


For Oceanaa Biotek Industries Limited



T Xavier Jeyaraj
Managing Director
Place: Chennai



For Abhay Jain & Co
Chartered Accountants
FRN: 000008S



CA A K JAIN
Partner
M No.: 070224




To
The Board of Directors,
Oceanaa Biotek Industries Limited

Dear Sir/Madam,

We hereby confirm the following in respect of the audited financial statements for the quarter and half yearly ended on 30th September, 2020 being presented before the Board at the meeting to be held on 11th November, 2020.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely



Place: **Chennai**
Date: **11.11.2020**

T Xavier Jeyaraj
Managing Director
DIN: 06896574